Gastric Cancer Diagnostic Procedure Market Research Reveals Path To $2.22 Billion By 2030

Understanding the future landscape of gastric cancer diagnostics reveals promising growth fueled by advancements in technology and increasing demand for early detection. This sector is evolving rapidly, driven by innovative procedures and novel testing methods that improve diagnostic accuracy and patient outcomes. Let's explore the projected market size, key players, emerging trends, and major segments defining the gastric cancer diagnostic procedure market.

Projected Growth Trajectory of the Gastric Cancer Diagnostic Procedure Market
The market for gastric cancer diagnostic procedures is anticipated to expand significantly, reaching a valuation of $2.23 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 7.7%, propelled by advancements in liquid biopsy techniques, the broader incorporation of molecular diagnostics, rising demand for early cancer detection, automation in diagnostic workflows, and the use of AI-enhanced imaging analysis. Key trends expected to influence the market's evolution include increased utilization of endoscopic diagnostics, greater adoption of molecular and genetic testing, heightened focus on detecting cancer at early stages, growth in non-invasive diagnostic approaches, and the integration of cutting-edge imaging technologies.

The gastric cancer diagnostic procedure market size has grown strongly in recent years. It will grow from $1.54 billion in 2025 to $1.65 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to use of endoscopy in gastric diagnosis, adoption of biopsy procedures, availability of imaging tests, hospital-based diagnostic infrastructure, development of pathology labs.

Download a free sample of the gastric cancer diagnostic procedure market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12038&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Leading Organizations Driving the Gastric Cancer Diagnostic Procedure Space
Several prominent corporations hold a strong presence in the gastric cancer diagnostic procedure market. These include Thermo Fisher Scientific Inc., Agilent Technologies Inc., Myriad Genetics Inc., Foundation Medicine Inc., Biocept Inc., Illumina Inc., Roche Diagnostics, QIAGEN N V, Bio-Rad Laboratories Inc., Siemens Healthineers, Danaher Corporation, Becton dic*kinson, bioMérieux SA, PerkinElmer Inc., NeoGenomics Laboratories, Guardant Health Inc., Natera Inc., Caris Molecular Diagnostics, Adaptive Biotechnologies Corp, and 10x Genomics Inc.
A notable development occurred in March 2023 when Pfizer, a US-based pharmaceutical giant, acquired Seagen Inc. for $43 billion. This acquisition bolsters Pfizer's oncology portfolio by incorporating Seagen's innovative antibody-drug conjugate (ADC) technology and expanding its offerings of breakthrough cancer therapies. Seagen Inc. is a biotechnology firm specialized in developing transformative cancer medicines.

Recent Innovations and Opportunities Shaping Market Dynamics
Key players in the gastric cancer diagnostic procedure sector are concentrating efforts on advancing technologies such as dual cell-free and exosomal microRNA (miRNA) liquid biopsy assays, which detect small noncoding RNAs circulating freely or within tumor-derived exosomes in the bloodstream. These assays enable highly sensitive and specific gastric cancer detection from a simple blood sample. For example, in December 2024, Cizzle Bio, a US-based biotech company, launched its DEX G2 blood test. This test combines cell-free and exosomal miRNAs to deliver roughly 95% sensitivity and 97% specificity, offering a less invasive alternative to traditional endoscopy. Although this innovation promises earlier diagnosis and broader screening potential, its widespread adoption may be limited by regulatory hurdles and the need for real-world validation studies.

View the full gastric cancer diagnostic procedure market report:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Market Share Leaders Within Gastric Cancer Diagnostic Procedure Segments
The gastric cancer diagnostic procedure market is divided into several detailed segments:
1) By Procedure Type: Endoscopic Procedure, Biopsy, Tissue Tests, Lab Tests, In-Vitro Diagnostic Tests, Imaging Tests, Molecular Diagnostics, Multiplexing Molecular Diagnostics, Immunoassays, and Other Procedure Types
2) By Symptom Type: Symptomatic and Asymptomatic
3) By Offering Type: Instruments, Reagents and Consumables, Services
4) By Body Fluid Type: Blood, Urine, Saliva, Stomach Juice, Tissue, and Other Body Fluids
5) By Disease Indication: Early Gastric Cancer and Advanced Gastric Cancer

Further breakdown includes:
- Endoscopic Procedures such as Upper Endoscopy (EGD) and Endoscopic Ultrasound (EUS)
- Biopsies including Endoscopic Biopsy and Fine Needle Aspiration (FNA) Biopsy
- Tissue Tests like Histopathology and Immunohistochemistry
- Lab Tests covering Blood Tests and Tumor Markers
- In-Vitro Diagnostics featuring Genetic Testing and Molecular Profiling
- Imaging Tests including Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET)
- Molecular Diagnostics such as PCR Testing and Next-Generation Sequencing (NGS)
- Multiplexing Molecular Diagnostics involving Multiplex PCR and Microarray Analysis
- Immunoassays like Enzyme-Linked Immunosorbent Assay (ELISA) and Radioimmunoassay (RIA)
- Other Procedures comprising Breath Tests and Liquid Biopsies

This comprehensive segmentation allows for targeted strategies and tailored solutions to better address various diagnostic needs in gastric cancer detection and management.

Expanded capabilities in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.